Kiniksa Pharmaceuticals International : Jefferies 2025 Presentation

Published: 2025-06-05 13:12:06 ET KNSA

Published on 06/05/2025 at 13:12

Jefferies Global Healthcare Conference

JUNE 5 , 2025

Aiming to address unmet needs by advancing novel therapies, prioritizing cardiovascular indications

Established leadership in

recurrent pericarditis market

Expected 2025 ARCALYST net

revenue of $590-$605M

Continued growth potential with

only ~13% penetration into target

population1

Advancing Clinical

Portfolio

Developing KPL-387 in recurrent

pericarditis

KPL-387 Phase 2/3 trial is expected

to initiate in mid-2025; Phase 2 data expected in 2H 2026

IND-enabling activities with

KPL-1161

Maintaining Strong

Financial Position

Q1 2025 cash reserves of ~$268M

Current operating plan expected to

remain cash flow positive on an annual basis

Optionality to invest in additional

value creation

1) As of year-end 2024.

3

Developing novel therapies for diseases with unmet need, prioritizing cardiovascular indications

Program

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Commercial

SPECIALTY CARDIOVASCULAR

ARCALYST® (rilonacept)1-3

IL-1α & IL-1β Trap

Recurrent Pericarditis

Cardiac Sarcoidosis

Collaborative Study Agreement with Mayo Clinic & The Johns Hopkins University

KPL-387

IL-1 Antagonist mAb

Recurrent Pericarditis

KPL-1161

Fc-Modified IL-1 Antagonist mAb

Undisclosed

OTHER (NON-CARDIOVASCULAR)

Abiprubart

Anti-CD40 mAb

Exploring Strategic Alternatives

Program

Licensee

Exclusive Licensed Territory

OUT-LICENSING AGREEMENTS

ARCALYST (rilonacept)

IL-1α & IL-1β Trap

Huadong Medicine

Asia Pacific Region, Excluding Japan

Vixarelimab

Anti-OSMRβ mAb

Roche and Genentech

Worldwide

4

1) Approved in the U.S.; ARCALYST is also approved in the U.S. for cryopyrin-associated periodic syndromes (CAPS) and deficiency of the interleukin-1 receptor antagonist (DIRA); 2) The FDA granted Breakthrough Therapy designation to ARCALYST for recurrent pericarditis in 2019; the FDA granted Orphan Drug exclusivity to ARCALYST in March 2021 for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and pediatric patients 12 years and older. The European Commission granted Orphan Drug designation to ARCALYST for the treatment of idiopathic pericarditis in 2021; 3) Kiniksa has worldwide rights, excluding the Middle East and North Africa; Kiniksa granted Huadong Medicine exclusive rights in the Asia Pacific Region, excluding Japan.

IL-1α = interleukin-1α; IL-1β = interleukin-1β; IL-1 = interleukin-1; mAb = monoclonal antibody; OSMRβ = oncostatin M receptor beta

~75%

YoY Growth

$137.8M

$78.9M

$42.7M

$22.2M

(% of Completed Cases)

~30 months

>90%

Q1 2022 Q1 2023 Q1 2024 Q1 2025

1) Data since launch through 3/31/2025

5

Disclaimer

Kiniksa Pharmaceuticals International plc published this content on June 05, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on June 05, 2025 at 17:11 UTC.